Drug Discovery & Pharmaceuticals

RSS

IU Cancer Center awarded grant to train next generation of cancer drug discovery researchers

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center was awarded a prestigious grant to train the next generation of cancer drug discovery and development researchers.

10 Oct 2023

New method produces highly pure mRNA vaccines with less inflammation risk

A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.

10 Oct 2023

Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.

From Owlstone Medical Ltd 10 Oct 2023

Researchers spearhead a new method to hone in on new cancer drug targets

Searching for new ways to block the growth of cancer cells is like looking for a needle in a haystack. Tumor cells rely on thousands of proteins to function, but only a few of those proteins can be precisely targeted by drugs to treat cancer safely and effectively.

5 Oct 2023

Unlocking the future of cancer care: Overcoming challenges in personalized neoantigen vaccine development

Challenges associated with the development and design of neoantigen cancer vaccines.

5 Oct 2023

Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a PhD student in the Institute of Chemical Biology EPSRC Centre for Doctoral Training (CDT) in Chemical Biology, at Imperial College London.

From Ubiquigent Limited 4 Oct 2023

Double-layer polysaccharide hydrogel overcomes challenges of probiotic delivery

In a groundbreaking study, a research team led by Changhu Xue and Xiangzhao Mao from the Ocean University of China has developed a remarkable double-layer polysaccharide hydrogel (DPH) that promises to revolutionize the field of intestine-targeted oral delivery of probiotics.

28 Sep 2023

SRI spins off a biosciences platform that accelerates drug discovery

SRI International announced today it is spinning off Synfini, a biosciences platform that accelerates the process by which pharmaceutical and other companies can design, synthesize, and bring to market molecules for drug development.

26 Sep 2023

Research presents new approach to identify therapeutic targets for human diseases associated with protein phase separation

Recent research demonstrates that protein phase separation (PPS) is widely present in cells and drives a variety of important biological functions.

25 Sep 2023

Machine learning speeds up virtual drug screening by 10-fold

Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed up with industry and supercomputers to carry out one of the world's largest virtual drug screens.

22 Sep 2023

CST and Leica Biosystems partner to enable companion diagnostics for personalized medicine

Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, is partnered with Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, to support the development of companion diagnostics (CDx) assays using the extensive portfolio of best-in-class antibodies from CST validated for immunohistochemistry (IHC).

From Cell Signaling Technology 20 Sep 2023

LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

From LabGenius 19 Sep 2023

MGI Partners with National Cancer Centre Singapore to Undergo Comprehensive Genomic Profiling of Asian-Prevalent Cancers

MGI Tech Singapore Pte, Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore ("NCCS") to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI's core DNBSEQ™ technology.

From MGI 18 Sep 2023

MGI Introduces New Chapter in Smart Laboratory Management with Official Opening of αLab in HKSTP

MGI, a company committed to building core tools and technology to lead life science, today announced the official opening of αLab in the Hong Kong Science & Technology Parks ("HKSTP"), the city's largest R&D base and one of the most important incubators.

From MGI 18 Sep 2023

Oral SARS-CoV-2 vaccine shows promise in monkeys

A new paper in Biology Methods and Protocols, published by Oxford University Press, indicates that researchers studying SARS-CoV-2 may have developed new methods to administer vaccines orally, which would be both easier to administer and more effective at combatting illnesses.

13 Sep 2023

Kuano closes £1.8M seed funding round to validate quantum simulation platform for drug discovery

Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, today announced the close of its £1.8M seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other Angel investors.

From Kuano Ltd. 13 Sep 2023

New machine-learning algorithms can help optimize the next-generation of therapeutic antibodies

Antibody treatments may be able to activate the immune system to fight diseases like Parkinson’s, Alzheimer’s and colorectal cancer, but they are less effective when they bind with themselves and other molecules that aren’t markers of disease.

11 Sep 2023

UTSA researchers study the mechanism of action of Sweet Annie's medicinal compounds

Vibrant green leaves sprout from tall fragrant plants sitting neatly in two rows of terracotta pots in Valerie Sponsel's UTSA biology laboratory.

8 Sep 2023

MD Anderson and Panacea create Manaolana Oncology to develop novel portfolio of monoclonal antibodies

The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.

6 Sep 2023

Waters Corporation and Princeton University announce multi-year research collaboration

Waters Corporation announced a multi-year research collaboration with Princeton University that will enable scientists, faculty, and students to work together to bring their diverse skills and backgrounds to solve complex challenges in biochemistry and materials science.

From Waters Corporation 24 Aug 2023